Omnicell (NASDAQ:OMCL) Sets New 1-Year Low at $25.34

Omnicell, Inc. (NASDAQ:OMCL)’s share price reached a new 52-week low on Tuesday . The stock traded as low as $25.34 and last traded at $25.38, with a volume of 147827 shares traded. The stock had previously closed at $26.29.

Analyst Ratings Changes

Several brokerages have issued reports on OMCL. Benchmark reissued a “buy” rating and set a $38.00 target price on shares of Omnicell in a research note on Tuesday, April 30th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $42.20.

Omnicell Stock Performance

The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -58.20, a price-to-earnings-growth ratio of 93.23 and a beta of 0.80. The firm’s 50 day moving average is $29.25 and its 200-day moving average is $29.84. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The company had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. Sell-side analysts anticipate that Omnicell, Inc. will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Neo Ivy Capital Management bought a new position in shares of Omnicell during the 3rd quarter worth about $78,000. EntryPoint Capital LLC raised its holdings in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares in the last quarter. CWM LLC lifted its position in shares of Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the period. Benjamin Edwards Inc. grew its holdings in shares of Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares in the last quarter. Finally, Strs Ohio increased its position in shares of Omnicell by 28.2% during the fourth quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after purchasing an additional 1,100 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.